MECNY logo

Menicon Co Ltd (MECNY)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Menicon Co Ltd (MECNY) trades at $88.63 with AI Score 55/100 (Hold). Menicon Co Ltd is a Japanese contact lens manufacturer involved in the production, sales, and distribution of a wide range of contact lenses and related products. Market cap: 108B, Sector: Healthcare.

Last analyzed: Mar 15, 2026
Menicon Co Ltd is a Japanese contact lens manufacturer involved in the production, sales, and distribution of a wide range of contact lenses and related products. The company also engages in the manufacturing and sales of medical instruments and supplies, as well as research and development of intraocular lenses.
55/100 AI Score MCap 108B Vol 100

Menicon Co Ltd (MECNY) Healthcare & Pipeline Overview

CEOKoji Kawaura
HeadquartersNagoya, US
IPO Year2021

Menicon Co Ltd, a global contact lens manufacturer, offers a diverse portfolio of soft and gas permeable lenses, lens care solutions, and medical devices. With a focus on innovation and quality, the company serves a broad customer base in the vision care market, facing competition from established players in the medical instruments and supplies sector.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Mar 15, 2026

Investment Thesis

Menicon Co Ltd presents a stable investment opportunity within the healthcare sector, driven by its established position in the contact lens market. The company's focus on innovation and expansion into related medical devices provides potential growth catalysts. However, the high P/E ratio of 11357.62 indicates a premium valuation. The company's low beta of 0.15 suggests lower volatility compared to the overall market. Key value drivers include continued demand for contact lenses, successful product launches, and strategic partnerships. Investors should monitor the company's ability to maintain market share and manage competitive pressures.

Based on FMP financials and quantitative analysis

Key Highlights

  • Menicon Co Ltd operates in the stable and growing contact lens market, driven by increasing rates of myopia and presbyopia worldwide.
  • The company's diversified product portfolio, including soft lenses, gas permeable lenses, and lens care products, caters to a wide range of customer needs.
  • Menicon's global presence, with operations in key markets, provides a strong foundation for future growth.
  • The company's commitment to research and development ensures a pipeline of innovative products and technologies.
  • Menicon's low beta of 0.15 indicates lower volatility compared to the overall market, potentially offering stability during economic downturns.

Competitors & Peers

Strengths

  • Established brand reputation and global presence.
  • Diversified product portfolio, including soft lenses, gas permeable lenses, and lens care products.
  • Strong research and development capabilities.
  • Extensive distribution network.

Weaknesses

  • High P/E ratio may indicate overvaluation.
  • Dependence on the contact lens market.
  • Limited presence in some emerging markets.
  • Exposure to currency fluctuations.

Catalysts

  • Upcoming: Potential new product launches in the contact lens or lens care segments within the next 12-18 months.
  • Ongoing: Increasing demand for contact lenses in emerging markets, driving revenue growth.
  • Ongoing: Continued investment in research and development, leading to innovative products and technologies.

Risks

  • Potential: Intense competition from established players in the contact lens market.
  • Potential: Regulatory changes and healthcare reforms that could impact the company's business.
  • Ongoing: Currency fluctuations that could affect the value of the ADR.
  • Ongoing: Limited liquidity and transparency due to trading on the OTC market.

Growth Opportunities

  • Expansion into Emerging Markets: Menicon can capitalize on the growing demand for vision care products in emerging markets, such as China and India. These markets offer significant growth potential due to their large populations, increasing disposable incomes, and rising awareness of vision correction options. By establishing a stronger presence in these regions, Menicon can tap into new customer segments and drive revenue growth. The timeline for significant market penetration is estimated at 3-5 years.
  • Development of Advanced Lens Technologies: Menicon can invest in the development of advanced lens technologies, such as extended-wear lenses, multifocal lenses, and lenses with enhanced oxygen permeability. These innovative products can address unmet customer needs and provide a competitive edge in the market. The company's research and development capabilities can be leveraged to create differentiated offerings that command premium pricing. Expect new product releases within 2-3 years.
  • Strategic Partnerships and Acquisitions: Menicon can pursue strategic partnerships and acquisitions to expand its product portfolio, geographic reach, and technological capabilities. Collaborations with other companies in the vision care industry can provide access to new markets, distribution channels, and innovative technologies. Acquisitions of smaller companies with complementary products or technologies can accelerate growth and enhance Menicon's competitive position. These deals could materialize within the next 1-2 years.
  • Focus on Specialty Lenses: Menicon can focus on the development and marketing of specialty lenses for specific vision conditions, such as keratoconus, presbyopia, and dry eye. These niche markets offer higher margins and less competition compared to the mainstream contact lens market. By catering to the unique needs of these patient populations, Menicon can build a loyal customer base and generate recurring revenue. Expect to see increased focus on specialty lenses within the next year.
  • Enhancement of Lens Care Solutions: Menicon can enhance its lens care solutions portfolio by developing innovative products that improve lens comfort, hygiene, and longevity. This includes multi-purpose solutions, cleaning solutions, and rewetting drops. By offering a comprehensive range of lens care products, Menicon can increase customer loyalty and generate additional revenue streams. New lens care solutions are expected to be released in the next 6-12 months.

Opportunities

  • Expansion into emerging markets.
  • Development of advanced lens technologies.
  • Strategic partnerships and acquisitions.
  • Focus on specialty lenses.

Threats

  • Intense competition from established players.
  • Technological advancements that could disrupt the market.
  • Changing consumer preferences.
  • Regulatory changes and healthcare reforms.

Competitive Advantages

  • Strong brand recognition and reputation for quality in the contact lens market.
  • Extensive distribution network and relationships with eye care professionals.
  • Proprietary lens technologies and materials that provide a competitive advantage.
  • Commitment to research and development, leading to a pipeline of innovative products.

About MECNY

Menicon Co Ltd was founded in 1951 by Kyoichi Tanaka in Nagoya, Japan, with the vision of improving vision care through innovative contact lens technology. Starting as a small workshop, the company pioneered the development of Japan's first corneal contact lenses. Over the decades, Menicon expanded its product line to include a comprehensive range of soft contact lenses, gas permeable lenses, and lens care products. The company has also diversified into the manufacturing and sales of medical instruments and supplies, as well as research and development of intraocular lenses. Menicon has established a global presence, with subsidiaries and distributors in numerous countries. The company's commitment to research and development has led to the introduction of advanced lens materials and designs, enhancing comfort, vision correction, and eye health. Menicon's product portfolio includes daily disposable lenses, frequent replacement lenses, and specialty lenses for various vision conditions. The company also offers a range of lens care solutions, including cleaning, disinfecting, and rewetting products. Menicon's dedication to quality and innovation has positioned it as a leading player in the contact lens industry, serving eye care professionals and patients worldwide.

What They Do

  • Manufactures and sells soft contact lenses for daily and extended wear.
  • Produces and distributes gas permeable contact lenses for various vision correction needs.
  • Offers a range of lens care products, including cleaning, disinfecting, and rewetting solutions.
  • Develops and manufactures medical instruments for ophthalmology and optometry.
  • Engages in research and development of intraocular lenses for cataract surgery.
  • Exports and imports contact lenses and related medical goods globally.

Business Model

  • Menicon generates revenue through the sale of contact lenses to eye care professionals and retailers.
  • The company also earns revenue from the sale of lens care products to consumers.
  • Menicon's business model includes the sale of medical instruments to hospitals and clinics.
  • The company invests in research and development to create innovative products and technologies, which drive future revenue growth.

Industry Context

Menicon Co Ltd operates within the medical instruments and supplies industry, which is characterized by technological advancements, stringent regulatory requirements, and increasing demand for innovative healthcare solutions. The global contact lens market is estimated to be worth billions of dollars, driven by the rising prevalence of vision disorders and the growing popularity of contact lenses as a convenient vision correction option. Menicon competes with established players in the industry, such as Johnson & Johnson, Alcon, and CooperVision, as well as smaller regional manufacturers. The company's success depends on its ability to differentiate its products, maintain quality standards, and adapt to changing market trends.

Key Customers

  • Eye care professionals, including optometrists and ophthalmologists.
  • Retailers and distributors of contact lenses and vision care products.
  • Hospitals and clinics that use medical instruments for eye examinations and surgeries.
  • Patients who require vision correction and use contact lenses.
AI Confidence: 71% Updated: Mar 15, 2026

Financials

Chart & Info

Menicon Co Ltd (MECNY) stock price: $88.63 (+0.00, +0.00%)

Latest News

No recent news available for MECNY.

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MECNY.

Price Targets

Wall Street price target analysis for MECNY.

MoonshotScore

55/100

What does this score mean?

The MoonshotScore rates MECNY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Koji Kawaura

CEO

Koji Kawaura serves as the CEO of Menicon Co Ltd. His career spans several decades in the healthcare and medical device industries. He has held various leadership positions within Menicon, contributing to the company's strategic growth and global expansion. Mr. Kawaura's expertise lies in product development, marketing, and international business management. He is known for his focus on innovation and customer satisfaction.

Track Record: Under Koji Kawaura's leadership, Menicon has expanded its global presence and introduced several innovative contact lens products. He has overseen strategic initiatives to strengthen the company's market position and enhance its brand reputation. His tenure has been marked by a commitment to research and development, resulting in advancements in lens technology and materials.

Menicon Co Ltd ADR Information Unsponsored

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that trades on U.S. stock exchanges. MECNY, as an ADR, allows U.S. investors to invest in Menicon Co Ltd without the complexities of cross-border transactions. Each MECNY ADR represents a specific number of Menicon Co Ltd's shares traded on its home market.

  • Home Market Ticker: Nagoya Stock Exchange, Japan
  • ADR Level: 1
  • ADR Ratio: 1:1
Currency Risk: As an ADR, MECNY is subject to currency risk. The value of the ADR can be affected by fluctuations in the exchange rate between the U.S. dollar and the Japanese Yen. If the Yen weakens against the dollar, the value of MECNY may decrease, even if the underlying stock price in Japan remains the same. Investors may want to evaluate this currency exposure when evaluating the potential returns and risks of investing in MECNY.
Tax Implications: Dividends paid on MECNY ADRs are subject to foreign dividend withholding tax by the Japanese government. The standard withholding tax rate is typically around 10-15%, but this may be reduced by tax treaties between the U.S. and Japan. U.S. investors may be able to claim a foreign tax credit on their U.S. tax return for the amount of foreign tax withheld.
Trading Hours: The Nagoya Stock Exchange (Japan) operates on different trading hours compared to U.S. stock exchanges. This means that there may be periods when the underlying Menicon Co Ltd shares are trading in Japan, but the MECNY ADR is not trading in the U.S. This can create opportunities for arbitrage but also introduces additional risks for investors.

MECNY OTC Market Information

The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market. Companies trading on this tier typically have limited or no financial disclosure requirements and may not meet the listing standards of major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of transparency and regulatory oversight compared to listed companies.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: Liquidity for MECNY on the OTC market is likely to be limited. Trading volume may be low, and the bid-ask spread may be wide, making it difficult to buy or sell shares at a desired price. Investors should be prepared for potential price volatility and execution challenges when trading MECNY on the OTC market.
OTC Risk Factors:
  • Limited financial disclosure and transparency.
  • Low trading volume and liquidity.
  • Potential for price manipulation and fraud.
  • Higher risk of delisting or suspension of trading.
  • Limited regulatory oversight.
Due Diligence Checklist:
  • Verify the company's registration and legal status.
  • Obtain and review any available financial statements.
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Understand the risks associated with investing in OTC stocks.
  • Consult with a financial advisor before making any investment decisions.
  • Check for any news or regulatory filings related to the company.
Legitimacy Signals:
  • Established history as a contact lens manufacturer.
  • Global presence and distribution network.
  • Commitment to research and development.
  • Presence of an ADR, suggesting some level of international recognition.
  • CEO with relevant industry experience.

Common Questions About MECNY

What does Menicon Co Ltd do?

Menicon Co Ltd is a global contact lens manufacturer that develops, produces, and distributes a wide range of contact lenses, including soft lenses, gas permeable lenses, and specialty lenses. The company also offers a comprehensive portfolio of lens care products, such as cleaning, disinfecting, and rewetting solutions. In addition to contact lenses, Menicon manufactures and sells medical instruments and supplies, as well as conducts research and development of intraocular lenses. The company serves eye care professionals and patients worldwide.

What do analysts say about MECNY stock?

Due to MECNY's OTC listing and ADR Level 1 status, comprehensive analyst coverage is limited. Key valuation metrics, such as the high P/E ratio of 11357.62, should be considered in the context of the company's growth prospects and industry dynamics. Investors should conduct their own independent research and consult with a financial advisor before making any investment decisions. The company's low beta of 0.15 suggests lower volatility compared to the overall market.

What are the main risks for MECNY?

The main risks for Menicon Co Ltd include intense competition from established players in the contact lens market, potential regulatory changes and healthcare reforms, currency fluctuations that could affect the value of the ADR, and limited liquidity and transparency due to trading on the OTC market. Additionally, the company's high P/E ratio may indicate overvaluation. Investors should carefully consider these risks before investing in MECNY.

What are the key factors to evaluate for MECNY?

Menicon Co Ltd (MECNY) currently holds an AI score of 55/100, indicating moderate score. The stock trades at a P/E of 11405.5x, above the S&P 500 average (~20-25x), suggesting high growth expectations. Key strength: Established brand reputation and global presence.. Primary risk to monitor: Potential: Intense competition from established players in the contact lens market.. This is not financial advice.

How frequently does MECNY data refresh on this page?

MECNY prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven MECNY's recent stock price performance?

Recent price movement in Menicon Co Ltd (MECNY) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established brand reputation and global presence.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider MECNY overvalued or undervalued right now?

Determining whether Menicon Co Ltd (MECNY) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 11405.5. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying MECNY?

Before investing in Menicon Co Ltd (MECNY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Limited information available due to OTC listing and ADR Level 1 status.
  • Financial data may not be readily available or up-to-date.
Data Sources

Popular Stocks